Radiopharmaceuticals Market Trends, Size, Top Players 2031
The radiopharmaceuticals market size is projected to reach US$ 26.51 billion by 2031 from US$ 9.07 billion in 2023. The market is expected to register a CAGR of 14.4% during 2023–2031. The evolving radiopharmacy facilities using advanced diagnostic techniques are likely to bring in new trends in the radiopharmaceuticals market.
Radiopharmaceuticals Market Analysis
Chronic diseases such as cardiovascular disease (CVD) and cancer are becoming more common in the aging population. The need for medical interventions, such as using radiopharmaceuticals to detect and treat age-related diseases, is increasing as the world's population advances in age. Increasing awareness of early disease detection leads to increasing use of radiopharmaceuticals for diagnostic imaging procedures such as single-photon emission computed tomography (SPECT) and positron emission tomography (PET) scans. These techniques enable accurate identification and characterization of various diseases, including cancer, heart disease, and neurological disorders, leading to a growing need for more radiopharmaceuticals. Cancer continues to be a major global health problem, and radiopharmaceuticals play a critical role in both cancer diagnosis and treatment. PET scans with radiotracers such as fluorodeoxyglucose (FDG)-PET are highly effective for cancer detection and monitoring. Therapeutic radiopharmaceuticals such as radioiodine for thyroid cancer and radioyttrium for lymphoma treatment offer targeted therapy options. The increasing prevalence of cancer and the development of new radiopharmaceutical cancer therapies are key growth drivers. In addition, partnerships between pharmaceutical companies, academic institutions, and healthcare providers enhance the development and commercialization of radiopharmaceutical drugs and provide future growth opportunities for the market.
Radiopharmaceuticals Market Overview
In recent years, radiopharmaceuticals have become one of the most effective techniques in various fields, including neurology, cardiology, and oncology. Each radiopharmaceutical targets a specific area in the body and releases radioactive substances to attack tumor cells once it reaches its location. Researchers have identified radiopharmaceuticals that can work against tumors such as thyroid carcinoma, brain tumors, lymphoma, and bone cancer. Traditional chemotherapy methods for cancer treatment are replaced with more practical therapeutic radiopharmaceuticals, opening up new market opportunities. Compared to X-rays and other external radiation imaging systems, radiopharmaceuticals assist doctors in diagnosing and providing a convenient and safer alternative for patients. Radiopharmaceuticals that are used for diagnostic purposes are called tracers. The amount of radiation released from diagnostic radiopharmaceuticals is lower than that of therapeutic radiopharmaceuticals. Developments in medical imaging technology, increasing rates of chronic diseases, and growing emphasis on personalized therapy contribute to the significant growth of the radiopharmaceuticals market. Nuclear medicine relies heavily on radiopharmaceuticals that are produced from radioisotopes bound to drugs, enabling imaging and treatment of various diseases.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Radiopharmaceuticals Market: Strategic Insights
Market Size Value in US$ 7,550.74 Million in 2021 Market Size Value by US$ 13,818.17 Million by 2028 Growth rate CAGR of 9.0% from 2021-2028 Forecast Period 2021-2028 Base Year 2021
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Radiopharmaceuticals Market: Strategic Insights
![radiopharmaceuticals-market](https://www.theinsightpartners.com/assets/rdimages/radiopharmaceuticals-market-img1.png)
Market Size Value in | US$ 7,550.74 Million in 2021 |
Market Size Value by | US$ 13,818.17 Million by 2028 |
Growth rate | CAGR of 9.0% from 2021-2028 |
Forecast Period | 2021-2028 |
Base Year | 2021 |
![Analyst Image](https://www.theinsightpartners.com/assets/mrinal_kerhalkar.jpg)
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
![Analyst Image](https://www.theinsightpartners.com/assets/images/speak_analyst.gif)
Radiopharmaceuticals Market Drivers and Opportunities
Growing Number of Clinical Trials in Targeted Therapy to Favor Market
Alpha particles have proven to be a new source for internal radiation therapy. They are highly cytotoxic, but their effect is highly targeted compared to therapies that use beta particles. Although targeted alpha therapy is in the development phase, it offers hope for life to cancer patients who do not respond to other treatment modalities. Developments in alpha particle-emitting radionuclides have shown promising results in delivering a highly localized dose of radiation targeted to cancer cells and minimizing damage to surrounding healthy tissue. Alpha particle-emitting radionuclides have a high linear energy transfer and a short range in tissue, making them suitable for the targeted therapy of certain types of cancer. The rise in awareness about alpha radioimmunotherapy and the surge in the availability of therapies for cancer treatment procedures are propelling the demand for nuclear imaging. Thus, the growing inclination toward the use of alpha radioimmunotherapy in the treatment of cancer is fuelling the radiopharmaceuticals market growth.
High Growth Potential in Developing Countries
Many medical market players focus on emerging countries in Asia, South America, and Africa due to a rise in the prevalence of various diseases in these regions. The medical field in India is growing rapidly, and it has undergone several significant changes over the last few decades. Research organizations in developing countries are engaged in the development of advanced diagnosis systems, including cost-effective and high-performance PET/SPECT systems. Developments are mainly aimed at extending their reach to remote areas where advanced medical IT facilities are not accessible. China, Japan, and Brazil, among other emerging countries, are spending heavily on the development of PET/SPECT machines to lower their costs and offer hospitals and other medical organizations better access to these machines. In March 2021, BWXT Medical Ltd. and Global Medical Solutions, Ltd. (GMS) entered into a joint venture to manufacture and distribute radioisotopes and radiopharmaceuticals in Asia Pacific. Thus, developing countries are offering significant opportunities to the radiopharmaceuticals market players to expand their reach and clientele.
Radiopharmaceuticals Market Report Segmentation Analysis
Key segments that contributed to the derivation of the radiopharmaceuticals market analysis are application, tracer type, and end user.
- By application, the market is segmented into oncology, cardiology, neurology, pulmonary, urology, and others. In 2023, oncology segment held the largest share of the market and is anticipated to register the highest CAGR during 2023–2031.
- Based on type, the radiopharmaceuticals market is bifurcated into diagnostic and therapeutic. In 2023, diagnostic segment held a larger share of the market and is estimated to register a higher CAGR from 2023 to 2031.
- By tracer type, the market is segmented into Tc-99m, F-18, Ga-68, TL-201, I-131, Fe-59, Lu-171, RB-82 and N-13, Cr-51 and P-32, Sc-46, Sg-269 and Hs-269, and others. In 2023, the Tc-99m segment held the largest share of the market and is anticipated to register the highest CAGR during 2023–2031.
- Based on end user, the radiopharmaceuticals market is divided into hospitals and clinics, diagnostic centers, academic and research institutes, and others. In 2023, the hospitals and clinics segment held the largest share of the market. The diagnostic centers segment is estimated to register the highest CAGR during 2023–2031.
Radiopharmaceuticals Market Share Analysis by Geography
The geographic scope of the radiopharmaceuticals market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America.
North America holds a dominant share in the radiopharmaceuticals market. The market growth in this region is due to increasing incidences of chronic diseases, supportive government plans, growing strategic initiatives by the market players, and development of innovative radiotherapies. The US holds the largest share of the radiopharmaceuticals market in North America. The market is expected to grow owing to the availability of advanced healthcare infrastructure, rising incidence and prevalence of target conditions, and product innovations by key players operating in the region. Also, innovative products have been launched by the players operating in the market to offer better treatment. For instance, in September 2022, MD Anderson Cancer Center and Radiopharm Theranostics launched Radiopharm Ventures, LLC, a joint venture for developing novel radiopharmaceutical therapeutic products for cancer.
Radiopharmaceuticals Market Report Scope
Radiopharmaceuticals Market News and Recent Developments
The radiopharmaceuticals market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the radiopharmaceuticals market are listed below:
- Curium announced that it has entered into an agreement with Eczacıbaşı Holding and Bozlu Group for the acquisition of Eczacıbaşı-Monrol Nuclear Product Co. (Monrol), a dedicated specialist in nuclear medicine. The acquisition is expected to bring together highly complementary geographical footprints, lutetium-177 (Lu-177) capabilities, and PET & SPECT nuclear medicine infrastructure, as well as facilitate the development of cutting-edge radionuclides and radiopharmaceuticals pipelines for diagnostic and therapeutic purposes. (Source: Curium, Press Release, April 2024)
- Novartis announced that it has received approval from the US Food and Drug Administration (FDA) for commercial manufacturing of Pluvicto (INN: lutetium (177Lu) vipivotide tetraxetan / USAN: lutetium Lu 177 vipivotide tetraxetan) at its new large-scale, state-of-the-art radioligand therapy (RLT) manufacturing facility in Indianapolis, Indiana, US. (Source: Novartis, Press Release, January 2024)
- IBA Radiopharma Solutions, CMI Inc., and Life Molecular Imaging (LMI) announced that the Japanese Ministry of Health approved the reimbursement by governmental health insurance of the amyloid Positron Emission Tomography (PET) diagnostic Neuraceq (florbetaben 18F). Amyloid-PET imaging using agents like Neuraceq is used in the diagnosis of Alzheimer's disease and other forms of cognitive impairment. It detects amyloid plaques in the brain, characteristic markers of Alzheimer's disease. (Source: IBA, Press Release, December 2023)
- Telix received Health Canada approval for its Illuccix, a kit for the preparation of gallium (68Ga) gozetotide injection. The product can be used in staging and re-staging intermediate and high-risk prostate cancer and localizing tumor tissue in recurrent prostate cancer. Illuccix was the first PSMA PET imaging agent that was granted regulatory approval in Canada. Health Canada was the third regulatory body worldwide to approve Illuccix, which is commercially available in Australia and the US. (Source: Telix, Press Release, October 2022)
- GE Healthcare and Minerva Imaging entered into a strategic partnership to accelerate the commercial launch of targeted radionuclide therapies (theranostics). Radionuclide therapy is a form of precision medicine where a radioactive substance is administered through the bloodstream to target cancer cells and irradiate them specifically. This helps reduce potential side effects compared to traditional cancer therapies. (Source: GE Healthcare, Press Release, December 2021)
Radiopharmaceuticals Market Report Coverage and Deliverables
The “Radiopharmaceuticals Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering the following areas:
- Radiopharmaceuticals market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
- Radiopharmaceuticals market trends as well as market dynamics such as drivers, restraints, and key opportunities
- Detailed PEST/Porter’s Five Forces and SWOT analysis
- Radiopharmaceuticals market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
- Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the radiopharmaceuticals market
- Detailed company profiles
![Report Coverage](https://www.theinsightpartners.com/assets/rdimages/report_coverage.png)
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
![Segment Covered](https://www.theinsightpartners.com/assets/rdimages/segment_covered.png)
Segment Covered
Type , Product Type , Application , and End User
![Regional Scope](https://www.theinsightpartners.com/assets/rdimages/regional_scope.png)
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
![Country Scope](https://www.theinsightpartners.com/assets/rdimages/country_scope.png)
Country Scope
Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, RoAPAC, RoE, RoMEA, RoSCAM, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States
Frequently Asked Questions
The radiopharmaceuticals market is expected to register a CAGR of 14.4% during 2023–2031.
The radiopharmaceuticals market is estimated to reach US$ 26.51 billion by 2031.
Evolving radiopharmacy facilities that use advanced diagnostic techniques in PET and radiotherapeutics are likely to bring in new trends in the radiopharmaceutical market.
Curium, ABX advanced biochemical compounds GmbH, and Medi-Radiopharma are among the leading players operating in the radiopharmaceuticals market.
North America dominated the radiopharmaceuticals market in 2023.
The rising prevalence of chronic diseases and the growing number of clinical trials in targeted therapy are the factors driving the radiopharmaceuticals market.
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Radiopharmaceuticals Market Landscape
4.1 Overview
4.2 PEST Analysis
4.3 Pricing Analysis
4.3.1 Regional Pricing Analysis, US$ (Per Dose)
5. Radiopharmaceuticals Market – Key Market Dynamics
5.1 Radiopharmaceuticals Market – Key Market Dynamics
5.2 Market Drivers
5.2.1 Rising Prevalence of Chronic Diseases
5.2.2 Growing Number of Clinical Trials in Targeted Therapy
5.3 Market Restraints
5.3.1 Short Shelf-Life of Radiopharmaceuticals
5.4 Market Opportunities
5.4.1 High Growth Potential in Developing Countries
5.5 Future Trends
5.5.1 Evolving Radiopharmacy Facilities
5.6 Impact of Drivers and Restraints:
6. Radiopharmaceuticals Market – Global Market Analysis
6.1 Radiopharmaceuticals Market Revenue (US$ Million), 2023–2031
7. Radiopharmaceuticals Market Analysis – by Application
7.1 Overview
7.2 Oncology
7.2.1 Overview
7.2.2 Oncology: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
7.3 Cardiology
7.3.1 Overview
7.3.2 Cardiology: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
7.4 Neurology
7.4.1 Overview
7.4.2 Neurology: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
7.5 Pulmonary
7.5.1 Overview
7.5.2 Pulmonary: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
7.6 Urology
7.6.1 Overview
7.6.2 Urology: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
7.7 Others
7.7.1 Overview
7.7.2 Others: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
8. Radiopharmaceuticals Market Analysis – by Type
8.1 Overview
8.2 Diagnostic
8.2.1 Overview
8.2.2 Diagnostic: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
8.2.2.1 Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – By Diagnostic
8.3 Therapeutic
8.3.1 Overview
8.3.2 Therapeutic: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
8.3.2.1 Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – By Therapeutic
9. Radiopharmaceuticals Market Analysis – by Tracer Type
9.1 Overview
9.2 Tc-99m
9.2.1 Overview
9.2.2 Tc-99m: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
9.2.2.1 Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – By Tc-99m
9.3 F-18
9.3.1 Overview
9.3.2 F-18: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
9.4 Ga-68
9.4.1 Overview
9.4.2 Ga-68: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
9.5 TL-201
9.5.1 Overview
9.5.2 TL-201: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
9.6 I-131
9.6.1 Overview
9.6.2 I-131: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
9.7 Fe-59
9.7.1 Overview
9.7.2 Fe-59: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
9.8 Lu-171
9.8.1 Overview
9.8.2 Lu-171: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
9.9 RB-82 and N-13
9.9.1 Overview
9.9.2 RB-82 and N-13: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
9.10 Cr-51 and P-32
9.10.1 Overview
9.10.2 Cr-51 and P-32: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
9.11 Sc-46
9.11.1 Overview
9.11.2 Sc-46: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
9.12 Sg-269 and Hs-269
9.12.1 Overview
9.12.2 Sg-269 and Hs-269: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
9.13 Others
9.13.1 Overview
9.13.2 Others: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
10. Radiopharmaceuticals Market Analysis – by End User
10.1 Overview
10.2 Hospitals and Clinics
10.2.1 Overview
10.2.2 Hospitals and Clinics: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
10.3 Diagnostic Centers
10.3.1 Overview
10.3.2 Diagnostic Centers: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
10.4 Academic and Research Institutes
10.4.1 Overview
10.4.2 Academic and Research Institutes: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
10.5 Others
10.5.1 Overview
10.5.2 Others: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
11. Radiopharmaceuticals Market – Geographical Analysis
11.1 Overview
11.2 North America
11.2.1 North America Radiopharmaceuticals Market Overview
11.2.2 North America: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
11.2.3 North America: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Application
11.2.4 North America: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Type
11.2.4.1 North America: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Diagnostic
11.2.4.2 North America: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Therapeutic
11.2.5 North America: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Tracer Type
11.2.5.1 North America: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Tc-99m
11.2.6 North America: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by End User
11.2.7 North America: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Country
11.2.7.1 United States: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
11.2.7.1.1 United States: Radiopharmaceuticals Market Breakdown, by Application
11.2.7.1.2 United States: Radiopharmaceuticals Market Breakdown, by Type
11.2.7.1.2.1 United States: Radiopharmaceuticals Market Breakdown, by Diagnostic
11.2.7.1.2.2 United States: Radiopharmaceuticals Market Breakdown, by Therapeutic
11.2.7.1.3 United States: Radiopharmaceuticals Market Breakdown, by Tracer Type
11.2.7.1.3.1 United States: Radiopharmaceuticals Market Breakdown, by Tc-99m
11.2.7.1.4 United States: Radiopharmaceuticals Market Breakdown, by End User
11.2.7.2 Canada: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
11.2.7.2.1 Canada: Radiopharmaceuticals Market Breakdown, by Application
11.2.7.2.2 Canada: Radiopharmaceuticals Market Breakdown, by Type
11.2.7.2.2.1 Canada: Radiopharmaceuticals Market Breakdown, by Diagnostic
11.2.7.2.2.2 Canada: Radiopharmaceuticals Market Breakdown, by Therapeutic
11.2.7.2.3 Canada: Radiopharmaceuticals Market Breakdown, by Tracer Type
11.2.7.2.3.1 Canada: Radiopharmaceuticals Market Breakdown, by Tc-99m
11.2.7.2.4 Canada: Radiopharmaceuticals Market Breakdown, by End User
11.2.7.3 Mexico: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
11.2.7.3.1 Mexico: Radiopharmaceuticals Market Breakdown, by Application
11.2.7.3.2 Mexico: Radiopharmaceuticals Market Breakdown, by Type
11.2.7.3.2.1 Mexico: Radiopharmaceuticals Market Breakdown, by Diagnostic
11.2.7.3.2.2 Mexico: Radiopharmaceuticals Market Breakdown, by Therapeutic
11.2.7.3.3 Mexico: Radiopharmaceuticals Market Breakdown, by Tracer Type
11.2.7.3.3.1 Mexico: Radiopharmaceuticals Market Breakdown, by Tc-99m
11.2.7.3.4 Mexico: Radiopharmaceuticals Market Breakdown, by End User
11.3 Europe
11.3.1 Europe Radiopharmaceuticals Market Overview
11.3.2 Europe: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
11.3.3 Europe: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Application
11.3.4 Europe: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Type
11.3.4.1 Europe: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Diagnostic
11.3.4.2 Europe: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Therapeutic
11.3.5 Europe: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Tracer Type
11.3.5.1 Europe: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Tc-99m
11.3.6 Europe: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by End User
11.3.7 Europe: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Country
11.3.7.1 Germany: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
11.3.7.1.1 Germany: Radiopharmaceuticals Market Breakdown, by Application
11.3.7.1.2 Germany: Radiopharmaceuticals Market Breakdown, by Type
11.3.7.1.2.1 Germany: Radiopharmaceuticals Market Breakdown, by Diagnostic
11.3.7.1.2.2 Germany: Radiopharmaceuticals Market Breakdown, by Therapeutic
11.3.7.1.3 Germany: Radiopharmaceuticals Market Breakdown, by Tracer Type
11.3.7.1.3.1 Germany: Radiopharmaceuticals Market Breakdown, by Tc-99m
11.3.7.1.4 Germany: Radiopharmaceuticals Market Breakdown, by End User
11.3.7.2 United Kingdom: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
11.3.7.2.1 United Kingdom: Radiopharmaceuticals Market Breakdown, by Application
11.3.7.2.2 United Kingdom: Radiopharmaceuticals Market Breakdown, by Type
11.3.7.2.2.1 United Kingdom: Radiopharmaceuticals Market Breakdown, by Diagnostic
11.3.7.2.2.2 United Kingdom: Radiopharmaceuticals Market Breakdown, by Therapeutic
11.3.7.2.3 United Kingdom: Radiopharmaceuticals Market Breakdown, by Tracer Type
11.3.7.2.3.1 United Kingdom: Radiopharmaceuticals Market Breakdown, by Tc-99m
11.3.7.2.4 United Kingdom: Radiopharmaceuticals Market Breakdown, by End User
11.3.7.3 France: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
11.3.7.3.1 France: Radiopharmaceuticals Market Breakdown, by Application
11.3.7.3.2 France: Radiopharmaceuticals Market Breakdown, by Type
11.3.7.3.2.1 France: Radiopharmaceuticals Market Breakdown, by Diagnostic
11.3.7.3.2.2 France: Radiopharmaceuticals Market Breakdown, by Therapeutic
11.3.7.3.3 France: Radiopharmaceuticals Market Breakdown, by Tracer Type
11.3.7.3.3.1 France: Radiopharmaceuticals Market Breakdown, by Tc-99m
11.3.7.3.4 France: Radiopharmaceuticals Market Breakdown, by End User
11.3.7.4 Italy: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
11.3.7.4.1 Italy: Radiopharmaceuticals Market Breakdown, by Application
11.3.7.4.2 Italy: Radiopharmaceuticals Market Breakdown, by Type
11.3.7.4.2.1 Italy: Radiopharmaceuticals Market Breakdown, by Diagnostic
11.3.7.4.2.2 Italy: Radiopharmaceuticals Market Breakdown, by Therapeutic
11.3.7.4.3 Italy: Radiopharmaceuticals Market Breakdown, by Tracer Type
11.3.7.4.3.1 Italy: Radiopharmaceuticals Market Breakdown, by Tc-99m
11.3.7.4.4 Italy: Radiopharmaceuticals Market Breakdown, by End User
11.3.7.5 Spain: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
11.3.7.5.1 Spain: Radiopharmaceuticals Market Breakdown, by Application
11.3.7.5.2 Spain: Radiopharmaceuticals Market Breakdown, by Type
11.3.7.5.2.1 Spain: Radiopharmaceuticals Market Breakdown, by Diagnostic
11.3.7.5.2.2 Spain: Radiopharmaceuticals Market Breakdown, by Therapeutic
11.3.7.5.3 Spain: Radiopharmaceuticals Market Breakdown, by Tracer Type
11.3.7.5.3.1 Spain: Radiopharmaceuticals Market Breakdown, by Tc-99m
11.3.7.5.4 Spain: Radiopharmaceuticals Market Breakdown, by End User
11.3.7.6 Rest of Europe: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
11.3.7.6.1 Rest of Europe: Radiopharmaceuticals Market Breakdown, by Application
11.3.7.6.2 Rest of Europe: Radiopharmaceuticals Market Breakdown, by Type
11.3.7.6.2.1 Rest of Europe: Radiopharmaceuticals Market Breakdown, by Diagnostic
11.3.7.6.2.2 Rest of Europe: Radiopharmaceuticals Market Breakdown, by Therapeutic
11.3.7.6.3 Rest of Europe: Radiopharmaceuticals Market Breakdown, by Tracer Type
11.3.7.6.3.1 Rest of Europe: Radiopharmaceuticals Market Breakdown, by Tc-99m
11.3.7.6.4 Rest of Europe: Radiopharmaceuticals Market Breakdown, by End User
11.4 Asia Pacific
11.4.1 Asia Pacific Radiopharmaceuticals Market Overview
11.4.2 Asia Pacific: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
11.4.2.1 Asia Pacific: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Application
11.4.2.2 Asia Pacific: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Type
11.4.2.2.1 Asia Pacific: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Diagnostic
11.4.2.2.2 Asia Pacific: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Therapeutic
11.4.2.3 Asia Pacific: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Tracer Type
11.4.2.3.1 Asia Pacific: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Tc-99m
11.4.2.4 Asia Pacific: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by End User
11.4.3 Asia Pacific: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Country
11.4.3.1 China: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
11.4.3.1.1 China: Radiopharmaceuticals Market Breakdown, by Application
11.4.3.1.2 China: Radiopharmaceuticals Market Breakdown, by Type
11.4.3.1.2.1 China: Radiopharmaceuticals Market Breakdown, by Diagnostic
11.4.3.1.2.2 China: Radiopharmaceuticals Market Breakdown, by Therapeutic
11.4.3.1.3 China: Radiopharmaceuticals Market Breakdown, by Tracer Type
11.4.3.1.3.1 China: Radiopharmaceuticals Market Breakdown, by Tc-99m
11.4.3.1.4 China: Radiopharmaceuticals Market Breakdown, by End User
11.4.3.2 Japan: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
11.4.3.2.1 Japan: Radiopharmaceuticals Market Breakdown, by Application
11.4.3.2.2 Japan: Radiopharmaceuticals Market Breakdown, by Type
11.4.3.2.2.1 Japan: Radiopharmaceuticals Market Breakdown, by Diagnostic
11.4.3.2.2.2 Japan: Radiopharmaceuticals Market Breakdown, by Therapeutic
11.4.3.2.3 Japan: Radiopharmaceuticals Market Breakdown, by Tracer Type
11.4.3.2.3.1 Japan: Radiopharmaceuticals Market Breakdown, by Tc-99m
11.4.3.2.4 Japan: Radiopharmaceuticals Market Breakdown, by End User
11.4.3.3 India: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
11.4.3.3.1 India: Radiopharmaceuticals Market Breakdown, by Application
11.4.3.3.2 India: Radiopharmaceuticals Market Breakdown, by Type
11.4.3.3.2.1 India: Radiopharmaceuticals Market Breakdown, by Diagnostic
11.4.3.3.2.2 India: Radiopharmaceuticals Market Breakdown, by Therapeutic
11.4.3.3.3 India: Radiopharmaceuticals Market Breakdown, by Tracer Type
11.4.3.3.3.1 India: Radiopharmaceuticals Market Breakdown, by Tc-99m
11.4.3.3.4 India: Radiopharmaceuticals Market Breakdown, by End User
11.4.3.4 Australia: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
11.4.3.4.1 Australia: Radiopharmaceuticals Market Breakdown, by Application
11.4.3.4.2 Australia: Radiopharmaceuticals Market Breakdown, by Type
11.4.3.4.2.1 Australia: Radiopharmaceuticals Market Breakdown, by Diagnostic
11.4.3.4.2.2 Australia: Radiopharmaceuticals Market Breakdown, by Therapeutic
11.4.3.4.3 Australia: Radiopharmaceuticals Market Breakdown, by Tracer Type
11.4.3.4.3.1 Australia: Radiopharmaceuticals Market Breakdown, by Tc-99m
11.4.3.4.4 Australia: Radiopharmaceuticals Market Breakdown, by End User
11.4.3.5 South Korea: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
11.4.3.5.1 South Korea: Radiopharmaceuticals Market Breakdown, by Application
11.4.3.5.2 South Korea: Radiopharmaceuticals Market Breakdown, by Type
11.4.3.5.2.1 South Korea: Radiopharmaceuticals Market Breakdown, by Diagnostic
11.4.3.5.2.2 South Korea: Radiopharmaceuticals Market Breakdown, by Therapeutic
11.4.3.5.3 South Korea: Radiopharmaceuticals Market Breakdown, by Tracer Type
11.4.3.5.3.1 South Korea: Radiopharmaceuticals Market Breakdown, by Tc-99m
11.4.3.5.4 South Korea: Radiopharmaceuticals Market Breakdown, by End User
11.4.3.6 Rest of APAC: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
11.4.3.6.1 Rest of APAC: Radiopharmaceuticals Market Breakdown, by Application
11.4.3.6.2 Rest of APAC: Radiopharmaceuticals Market Breakdown, by Type
11.4.3.6.2.1 Rest of APAC: Radiopharmaceuticals Market Breakdown, by Diagnostic
11.4.3.6.2.2 Rest of APAC: Radiopharmaceuticals Market Breakdown, by Therapeutic
11.4.3.6.3 Rest of APAC: Radiopharmaceuticals Market Breakdown, by Tracer Type
11.4.3.6.3.1 Rest of APAC: Radiopharmaceuticals Market Breakdown, by Tc-99m
11.4.3.6.4 Rest of APAC: Radiopharmaceuticals Market Breakdown, by End User
11.5 Middle East and Africa
11.5.1 Middle East and Africa Radiopharmaceuticals Market Overview
11.5.2 Middle East and Africa: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
11.5.2.1 Middle East and Africa: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Application
11.5.2.2 Middle East and Africa: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Type
11.5.2.2.1 Middle East and Africa: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Diagnostic
11.5.2.2.2 Middle East and Africa: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Therapeutic
11.5.2.3 Middle East and Africa: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Tracer Type
11.5.2.3.1 Middle East and Africa: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Tc-99m
11.5.2.4 Middle East and Africa: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by End User
11.5.3 Middle East and Africa: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Country
11.5.3.1 Saudi Arabia: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
11.5.3.1.1 Saudi Arabia: Radiopharmaceuticals Market Breakdown, by Application
11.5.3.1.2 Saudi Arabia: Radiopharmaceuticals Market Breakdown, by Type
11.5.3.1.2.1 Saudi Arabia: Radiopharmaceuticals Market Breakdown, by Diagnostic
11.5.3.1.2.2 Saudi Arabia: Radiopharmaceuticals Market Breakdown, by Therapeutic
11.5.3.1.3 Saudi Arabia: Radiopharmaceuticals Market Breakdown, by Tracer Type
11.5.3.1.3.1 Saudi Arabia: Radiopharmaceuticals Market Breakdown, by Tc-99m
11.5.3.1.4 Saudi Arabia: Radiopharmaceuticals Market Breakdown, by End User
11.5.3.2 South Africa: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
11.5.3.2.1 South Africa: Radiopharmaceuticals Market Breakdown, by Application
11.5.3.2.2 South Africa: Radiopharmaceuticals Market Breakdown, by Type
11.5.3.2.2.1 South Africa: Radiopharmaceuticals Market Breakdown, by Diagnostic
11.5.3.2.2.2 South Africa: Radiopharmaceuticals Market Breakdown, by Therapeutic
11.5.3.2.3 South Africa: Radiopharmaceuticals Market Breakdown, by Tracer Type
11.5.3.2.3.1 South Africa: Radiopharmaceuticals Market Breakdown, by Tc-99m
11.5.3.2.4 South Africa: Radiopharmaceuticals Market Breakdown, by End User
11.5.3.3 United Arab Emirates: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
11.5.3.3.1 United Arab Emirates: Radiopharmaceuticals Market Breakdown, by Application
11.5.3.3.2 United Arab Emirates: Radiopharmaceuticals Market Breakdown, by Type
11.5.3.3.2.1 United Arab Emirates: Radiopharmaceuticals Market Breakdown, by Diagnostic
11.5.3.3.2.2 United Arab Emirates: Radiopharmaceuticals Market Breakdown, by Therapeutic
11.5.3.3.3 United Arab Emirates: Radiopharmaceuticals Market Breakdown, by Tracer Type
11.5.3.3.3.1 United Arab Emirates: Radiopharmaceuticals Market Breakdown, by Tc-99m
11.5.3.3.4 United Arab Emirates: Radiopharmaceuticals Market Breakdown, by End User
11.5.3.4 Rest of Middle East and Africa: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
11.5.3.4.1 Rest of Middle East and Africa: Radiopharmaceuticals Market Breakdown, by Application
11.5.3.4.2 Rest of Middle East and Africa: Radiopharmaceuticals Market Breakdown, by Type
11.5.3.4.2.1 Rest of Middle East and Africa: Radiopharmaceuticals Market Breakdown, by Diagnostic
11.5.3.4.2.2 Rest of Middle East and Africa: Radiopharmaceuticals Market Breakdown, by Therapeutic
11.5.3.4.3 Rest of Middle East and Africa: Radiopharmaceuticals Market Breakdown, by Tracer Type
11.5.3.4.3.1 Rest of Middle East and Africa: Radiopharmaceuticals Market Breakdown, by Tc-99m
11.5.3.4.4 Rest of Middle East and Africa: Radiopharmaceuticals Market Breakdown, by End User
11.6 South and Central America
11.6.1 South and Central America Radiopharmaceuticals Market Overview
11.6.2 South and Central America: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
11.6.2.1 South and Central America: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Application
11.6.2.2 South and Central America: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Type
11.6.2.2.1 South and Central America: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Diagnostic
11.6.2.2.2 South and Central America: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Therapeutic
11.6.2.3 South and Central America: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Tracer Type
11.6.2.3.1 South and Central America: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Tc-99m
11.6.2.4 South and Central America: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by End User
11.6.3 South and Central America: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Country
11.6.3.1 Brazil: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
11.6.3.1.1 Brazil: Radiopharmaceuticals Market Breakdown, by Application
11.6.3.1.2 Brazil: Radiopharmaceuticals Market Breakdown, by Type
11.6.3.1.2.1 Brazil: Radiopharmaceuticals Market Breakdown, by Diagnostic
11.6.3.1.2.2 Brazil: Radiopharmaceuticals Market Breakdown, by Therapeutic
11.6.3.1.3 Brazil: Radiopharmaceuticals Market Breakdown, by Tracer Type
11.6.3.1.3.1 Brazil: Radiopharmaceuticals Market Breakdown, by Tc-99m
11.6.3.1.4 Brazil: Radiopharmaceuticals Market Breakdown, by End User
11.6.3.2 Argentina: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
11.6.3.2.1 Argentina: Radiopharmaceuticals Market Breakdown, by Application
11.6.3.2.2 Argentina: Radiopharmaceuticals Market Breakdown, by Type
11.6.3.2.2.1 Argentina: Radiopharmaceuticals Market Breakdown, by Diagnostic
11.6.3.2.2.2 Argentina: Radiopharmaceuticals Market Breakdown, by Therapeutic
11.6.3.2.3 Argentina: Radiopharmaceuticals Market Breakdown, by Tracer Type
11.6.3.2.3.1 Argentina: Radiopharmaceuticals Market Breakdown, by Tc-99m
11.6.3.2.4 Argentina: Radiopharmaceuticals Market Breakdown, by End User
11.6.3.3 Rest of South and Central America: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
11.6.3.3.1 Rest of South and Central America: Radiopharmaceuticals Market Breakdown, by Application
11.6.3.3.2 Rest of South and Central America: Radiopharmaceuticals Market Breakdown, by Type
11.6.3.3.2.1 Rest of South and Central America: Radiopharmaceuticals Market Breakdown, by Diagnostic
11.6.3.3.2.2 Rest of South and Central America: Radiopharmaceuticals Market Breakdown, by Therapeutic
11.6.3.3.3 Rest of South and Central America: Radiopharmaceuticals Market Breakdown, by Tracer Type
11.6.3.3.3.1 Rest of South and Central America: Radiopharmaceuticals Market Breakdown, by Tc-99m
11.6.3.3.4 Rest of South and Central America: Radiopharmaceuticals Market Breakdown, by End User
12. Radiopharmaceuticals Market-Industry Landscape
12.1 Overview
12.2 Growth Strategies in the Radiopharmaceuticals Market
12.3 Inorganic Growth Strategies
12.3.1 Overview
12.4 Organic Growth Strategies
12.4.1 Overview
13. Company Profiles
13.1 Cardinal Health Inc
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Curium
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 General Electric Co
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Medi-Radiopharma
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Rotem Industries Ltd
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 ABX advanced biochemical compounds GmbH
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Invicro LLC
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Newcastle University
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 Novartis AG
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Blue Earth Diagnostics Limited
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
13.11 IBA Radiopharma Solutions
13.11.1 Key Facts
13.11.2 Business Description
13.11.3 Products and Services
13.11.4 Financial Overview
13.11.5 SWOT Analysis
13.11.6 Key Developments
14. Appendix
14.1 About The Insight Partners
14.2 Glossary of Terms
List of Tables
Table 1. Radiopharmaceuticals Market Segmentation
Table 2. Regional Pricing Analysis, US$ (Per Dose), 2023
Table 3. Ongoing Targeted Alpha Therapy Clinical Trials
Table 4. Physical Half-Lives of Some Medical Radionuclides for Diagnostic and Therapeutic Use
Table 5. Some Other Radionuclides Used in Diagnostic Radiopharmaceuticals
Table 6. Some Other Radionuclides Used in Therapeutic Radiopharmaceuticals
Table 7. Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – By Diagnostic
Table 8. Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – By Therapeutic
Table 9. Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – By Tc-99m
Table 10. North America: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 11. North America: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 12. North America: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Diagnostic
Table 13. North America: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic
Table 14. North America: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tracer Type
Table 15. North America: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tc-99m
Table 16. North America: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 17. United States: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 18. United States: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 19. United States: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Diagnostic
Table 20. United States: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic
Table 21. United States: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tracer Type
Table 22. United States: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tc-99m
Table 23. United States: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 24. Canada: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 25. Canada: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 26. Canada: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Diagnostic
Table 27. Canada: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic
Table 28. Canada: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tracer Type
Table 29. Canada: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tc-99m
Table 30. Canada: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 31. Mexico: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 32. Mexico: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 33. Mexico: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Diagnostic
Table 34. Mexico: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic
Table 35. Mexico: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tracer Type
Table 36. Mexico: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tc-99m
Table 37. Mexico: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 38. Europe: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 39. Europe: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 40. Europe: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Diagnostic
Table 41. Europe: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic
Table 42. Europe: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tracer Type
Table 43. Europe: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tc-99m
Table 44. Europe: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 45. Germany: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 46. Germany: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 47. Germany: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Diagnostic
Table 48. Germany: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic
Table 49. Germany: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tracer Type
Table 50. Germany: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tc-99m
Table 51. Germany: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 52. United Kingdom: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 53. United Kingdom: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 54. United Kingdom: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Diagnostic
Table 55. United Kingdom: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic
Table 56. United Kingdom: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tracer Type
Table 57. United Kingdom: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tc-99m
Table 58. United Kingdom: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 59. France: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 60. France: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 61. France: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Diagnostic
Table 62. France: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic
Table 63. France: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tracer Type
Table 64. France: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tc-99m
Table 65. France: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 66. Italy: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 67. Italy: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 68. Italy: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Diagnostic
Table 69. Italy: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic
Table 70. Italy: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tracer Type
Table 71. Italy: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tc-99m
Table 72. Italy: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 73. Spain: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 74. Spain: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 75. Spain: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Diagnostic
Table 76. Spain: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic
Table 77. Spain: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tracer Type
Table 78. Spain: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tc-99m
Table 79. Spain: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 80. Rest of Europe: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 81. Rest of Europe: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 82. Rest of Europe: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Diagnostic
Table 83. Rest of Europe: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic
Table 84. Rest of Europe: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tracer Type
Table 85. Rest of Europe: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tc-99m
Table 86. Rest of Europe: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 87. Asia Pacific: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 88. Asia Pacific: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 89. Asia Pacific: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Diagnostic
Table 90. Asia Pacific: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic
Table 91. Asia Pacific: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tracer Type
Table 92. Asia Pacific: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tc-99m
Table 93. Asia Pacific: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 94. China: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 95. China: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 96. China: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Diagnostic
Table 97. China: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic
Table 98. China: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tracer Type
Table 99. China: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tc-99m
Table 100. China: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 101. Japan: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 102. Japan: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 103. Japan: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Diagnostic
Table 104. Japan: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic
Table 105. Japan: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tracer Type
Table 106. Japan: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tc-99m
Table 107. Japan: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 108. India: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 109. India: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 110. India: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Diagnostic
Table 111. India: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic
Table 112. India: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tracer Type
Table 113. India: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tc-99m
Table 114. India: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 115. Australia: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 116. Australia: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 117. Australia: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Diagnostic
Table 118. Australia: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic
Table 119. Australia: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tracer Type
Table 120. Australia: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tc-99m
Table 121. Australia: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 122. South Korea: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 123. South Korea: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 124. South Korea: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Diagnostic
Table 125. South Korea: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic
Table 126. South Korea: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tracer Type
Table 127. South Korea: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tc-99m
Table 128. South Korea: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 129. Rest of APAC: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 130. Rest of APAC: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 131. Rest of APAC: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Diagnostic
Table 132. Rest of APAC: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic
Table 133. Rest of APAC: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tracer Type
Table 134. Rest of APAC: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tc-99m
Table 135. Rest of APAC: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 136. Middle East and Africa: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 137. Middle East and Africa: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 138. Middle East and Africa: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Diagnostic
Table 139. Middle East and Africa: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic
Table 140. Middle East and Africa: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tracer Type
Table 141. Middle East and Africa: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tc-99m
Table 142. Middle East and Africa: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 143. Saudi Arabia: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 144. Saudi Arabia: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 145. Saudi Arabia: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Diagnostic
Table 146. Saudi Arabia: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic
Table 147. Saudi Arabia: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tracer Type
Table 148. Saudi Arabia: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tc-99m
Table 149. Saudi Arabia: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 150. South Africa: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 151. South Africa: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 152. South Africa: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Diagnostic
Table 153. South Africa: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic
Table 154. South Africa: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tracer Type
Table 155. South Africa: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tc-99m
Table 156. South Africa: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 157. United Arab Emirates: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 158. United Arab Emirates: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 159. United Arab Emirates: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Diagnostic
Table 160. United Arab Emirates: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic
Table 161. United Arab Emirates: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tracer Type
Table 162. United Arab Emirates: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tc-99m
Table 163. United Arab Emirates: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 164. Rest of Middle East and Africa: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 165. Rest of Middle East and Africa: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 166. Rest of Middle East and Africa: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Diagnostic
Table 167. Rest of Middle East and Africa: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic
Table 168. Rest of Middle East and Africa: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tracer Type
Table 169. Rest of Middle East and Africa: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tc-99m
Table 170. Rest of Middle East and Africa: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 171. South and Central America: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 172. South and Central America: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 173. South and Central America: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Diagnostic
Table 174. South and Central America: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic
Table 175. South and Central America: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tracer Type
Table 176. South and Central America: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tc-99m
Table 177. South and Central America: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 178. Brazil: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 179. Brazil: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 180. Brazil: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Diagnostic
Table 181. Brazil: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic
Table 182. Brazil: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tracer Type
Table 183. Brazil: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tc-99m
Table 184. Brazil: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 185. Argentina: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 186. Argentina: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 187. Argentina: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Diagnostic
Table 188. Argentina: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic
Table 189. Argentina: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tracer Type
Table 190. Argentina: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tc-99m
Table 191. Argentina: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 192. Rest of South and Central America: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 193. Rest of South and Central America: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 194. Rest of South and Central America: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Diagnostic
Table 195. Rest of South and Central America: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic
Table 196. Rest of South and Central America: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tracer Type
Table 197. Rest of South and Central America: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tc-99m
Table 198. Rest of South and Central America: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 199. Recent Inorganic Growth Strategies in the Radiopharmaceuticals Market
Table 200. Recent Organic Growth Strategies in the Radiopharmaceuticals Market
Table 201. Glossary of Terms, Radiopharmaceuticals Market
List of Figures
Figure 1. Radiopharmaceuticals Market Segmentation, by Geography
Figure 2. PEST Analysis
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Radiopharmaceuticals Market Revenue (US$ Million), 2023–2031
Figure 5. Bioprocessing Market Breakdown by Geography, 2023 and 2031 (%)
Figure 6. Radiopharmaceuticals Market Share (%) – by Application (2023 and 2031)
Figure 7. Oncology: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
Figure 8. Cardiology: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
Figure 9. Neurology: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
Figure 10. Pulmonary: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
Figure 11. Urology: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
Figure 12. Others: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
Figure 13. Radiopharmaceuticals Market Share (%) – by Type (2023 and 2031)
Figure 14. Diagnostic: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
Figure 15. Therapeutic: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
Figure 16. Radiopharmaceuticals Market Share (%) – by Tracer Type (2023 and 2031)
Figure 17. Tc-99m: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
Figure 18. F-18: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
Figure 19. Ga-68: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
Figure 20. TL-201: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
Figure 21. I-131: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
Figure 22. Fe-59: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
Figure 23. Lu-171: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
Figure 24. RB-82 and N-13: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
Figure 25. Cr-51 and P-32: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
Figure 26. Sc-46: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
Figure 27. Sg-269 and Hs-269: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
Figure 28. Others: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
Figure 29. Radiopharmaceuticals Market Share (%) – by End User (2023 and 2031)
Figure 30. Hospitals and Clinics: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
Figure 31. Diagnostic Centers: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
Figure 32. Academic and Research Institutes: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
Figure 33. Others: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
Figure 34. Radiopharmaceuticals Market Breakdown by Region, 2023 and 2031 (%)
Figure 35. North America: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million)
Figure 36. North America: Radiopharmaceuticals Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 37. United States: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million)
Figure 38. Canada: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million)
Figure 39. Mexico: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million)
Figure 40. Europe: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million)
Figure 41. Europe: Radiopharmaceuticals Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 42. Germany: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million)
Figure 43. United Kingdom: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million)
Figure 44. France: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million)
Figure 45. Italy: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million)
Figure 46. Spain: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million)
Figure 47. Rest of Europe: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million)
Figure 48. Asia Pacific: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million)
Figure 49. Asia Pacific: Radiopharmaceuticals Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 50. China: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million)
Figure 51. Japan: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million)
Figure 52. India: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million)
Figure 53. Australia: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million)
Figure 54. South Korea: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million)
Figure 55. Rest of APAC: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million)
Figure 56. Middle East and Africa: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million)
Figure 57. Middle East and Africa: Radiopharmaceuticals Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 58. Saudi Arabia: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million)
Figure 59. South Africa: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million)
Figure 60. United Arab Emirates: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million)
Figure 61. Rest of Middle East and Africa: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million)
Figure 62. South and Central America: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million)
Figure 63. South and Central America: Radiopharmaceuticals Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 64. Brazil: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million)
Figure 65. Argentina: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million)
Figure 66. Rest of South and Central America: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million)
Figure 67. Growth Strategies in the Radiopharmaceuticals Market
- Medi-Radiopharma (MRP)
- Rotem Industries Ltd.
- ABX Advanced Biochemical Compounds GmbH
- Invicro LLC
- Cardinal Health
- Newcastle University
- Novartis
- Curium
- Blue Earth Diagnostics
- General Electric Company
- IBA Radiopharma Solutions
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.